Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Demegestone is a synthetic steroidal progestin of the 19-norprogesterone class. It acts as a highly potent **agonist** of the **progesterone receptor** and was previously used to treat luteal insufficiency. Demegestone exhibits strong progestogenic activity (about 50 times that of progesterone in animal models) and has little or no androgenic activity; it may have some antiandrogenic effects. The drug also shows low affinity for glucocorticoid and mineralocorticoid receptors and its major metabolite is a moderately potent progestogen with weak mineralocorticoid activity. Demegestone was marketed in France under the brand name Lutionex but has since been discontinued. It was also studied in combination with estrogens as an oral contraceptive and for infertility treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on demegestone.